1. Home
  2. QFIN vs GH Comparison

QFIN vs GH Comparison

Compare QFIN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

HOLD

Current Price

$19.84

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$102.49

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QFIN
GH
Founded
2016
2011
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
14.1B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
QFIN
GH
Price
$19.84
$102.49
Analyst Decision
Buy
Strong Buy
Analyst Count
2
21
Target Price
$36.85
$96.48
AVG Volume (30 Days)
2.1M
1.9M
Earning Date
11-18-2025
10-29-2025
Dividend Yield
7.68%
N/A
EPS Growth
40.93
N/A
EPS
6.93
N/A
Revenue
$2,752,357,572.00
$902,569,000.00
Revenue This Year
$16.96
$35.00
Revenue Next Year
N/A
$26.80
P/E Ratio
$2.86
N/A
Revenue Growth
14.06
30.38
52 Week Low
$17.61
$29.91
52 Week High
$48.94
$112.43

Technical Indicators

Market Signals
Indicator
QFIN
GH
Relative Strength Index (RSI) 47.36 55.77
Support Level $18.71 $96.28
Resistance Level $20.05 $103.17
Average True Range (ATR) 0.67 3.88
MACD 0.26 -0.94
Stochastic Oscillator 81.72 48.56

Price Performance

Historical Comparison
QFIN
GH

About QFIN Qifu Technology Inc.

Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: